{"id":146428,"date":"2026-04-15T10:46:40","date_gmt":"2026-04-15T14:46:40","guid":{"rendered":"https:\/\/medcitynews.com\/?p=146428"},"modified":"2026-04-15T10:46:41","modified_gmt":"2026-04-15T14:46:41","slug":"eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly","status":"publish","type":"post","link":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/","title":{"rendered":"Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors"},"content":{"rendered":"<p>Antibody drug conjugates continue to be a robust area for research and dealmaking, and Eli Lilly\u2019s latest move in this space is the <a href=\"https:\/\/www.businesswire.com\/news\/home\/20260414133394\/en\/CrossBridge-Bio-Enters-an-Agreement-to-be-Acquired-by-Eli-Lilly-to-Advance-Next-Generation-Dual-Payload-Antibody-Drug-Conjugates\" target=\"_blank\" rel=\"noopener\">acquisition of CrossBridge Bio<\/a>, a preclinical startup with technology and a lead program that could bring patients more powerful cancer treatments.<\/p>\n<p>Lilly is paying up to $300 million for CrossBridge, according to deal terms announced Tuesday. The companies did not provide a financial breakdown, other than to say the sum spans an upfront payment and a subsequent payment for a development milestone that was not disclosed.<\/p>\n<p>In an ADC, a toxic drug payload is delivered to a tumor by leveraging the targeting ability of an antibody. Houston-based CrossBridge develops ADCs engineered to carry two drug payloads. This approach is intended to provide a wider therapeutic index, the dose range that balances safety and efficacy. It can also address mechanisms that cancers use to develop drug resistance.<\/p>\n<p>Lead CrossBridge program CBB-120 is designed to target TROP2, a protein expressed by many solid tumors including cancers of the breast and lungs. This target is already addressed by <a href=\"https:\/\/medcitynews.com\/2023\/02\/gilead-sciences-drug-wins-fda-approval-in-most-common-type-of-breast-cancer\/\" target=\"_blank\" rel=\"noopener\">Trodelvy, a blockbuster ADC marketed by Gilead Sciences for treating certain breast and bladder cancers<\/a>. Trodelvy\u2019s drug payload inhibits topoisomerase 1, an enzyme that\u2019s active in rapidly dividing cancer cells. CrossBridge\u2019s dual-payload ADC carries a topoisomerase 1 inhibitor and an inhibitor of ATR, a protein that promotes the survival of cancer cells. An investigational new drug (IND) application for CBB-120 is expected this year.<\/p>\n<p>CrossBridge was founded in 2023 based on ADC technology developed by Kyoji Tsuchikama, a professor of medicinal chemistry at the University of Texas Health Science Center at Houston. In 2024, CrossBridge announced <a href=\"https:\/\/www.businesswire.com\/news\/home\/20241104194597\/en\/CrossBridge-Bio-Secures-%2410-Million-Financing-to-Advance-the-Development-of-Next-Generation-Dual-Payload-ADC-Therapies\" target=\"_blank\" rel=\"noopener\">$10 million in seed financing<\/a> led by TMC Venture Fund and CE-Ventures. Last year, the Cancer Prevention and Research Institute of Texas awarded CrossBridge a <a href=\"https:\/\/www.businesswire.com\/news\/home\/20251120267912\/en\/CrossBridge-Bio-Awarded-%2415-Million-CPRIT-Grant-to-Advance-CBB-120-Its-Lead-Dual-Payload-ADC-Targeting-TROP-2-Into-the-Clinic\" target=\"_blank\" rel=\"noopener\">$15 million grant<\/a> to support IND-enabling studies for CBB-120.<\/p>\n<p>\u201cWe look forward to seeing how Lilly advances our new generation of dual-payload antibody-drug conjugates, including CBB-120, with the potential to meaningfully improve outcomes for patients with limited treatment options,\u201d CrossBridge co-founder and CEO Michael Torres said in a prepared statement. \u201cAt CrossBridge Bio, we believe our dual-payload ADC platform is uniquely positioned to be transformative in oncology.\u201d<\/p>\n<p>Lilly already has a presence in ADC R&amp;D. Its clinical-stage pipeline includes <a href=\"https:\/\/www.prnewswire.com\/news-releases\/lillys-sofetabart-mipitecan-receives-us-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer-302665319.html\" target=\"_blank\" rel=\"noopener\">sofetabart miptecan<\/a>, an ADC designed to target folate receptor alpha to treat platinum-resistant ovarian cancer. This drug is currently in Phase 3 testing. In 2023, Lilly <a href=\"https:\/\/heidelberg-pharma.com\/en\/press-investors\/announcements\/press-releases-and-ad-hoc-announcements\/ah-heidelberg-pharma-sells-minority-shareholding-in-emergence-therapeutics\" target=\"_blank\" rel=\"noopener\">purchased<\/a> Germany-based ADC developer Emergence Therapeutics. A Nectin-4-targeting ADC from the deal, ETx-22, is in preclinical development for urothelial cancer, according to <a href=\"https:\/\/www.sec.gov\/ix?doc=\/Archives\/edgar\/data\/0000059478\/000005947826000013\/lly-20251231.htm\" target=\"_blank\" rel=\"noopener\">Lilly\u2019s annual report<\/a>.<\/p>\n<p>Lilly\u2019s CrossBridge acquisition is the latest in a recent flurry of ADC business deals. Last week, <a href=\"https:\/\/medcitynews.com\/2026\/04\/gilead-sciences-tubulis-acquisition-ovarian-cancer-antibody-drug-conjugate-adc-gild\/\" target=\"_blank\" rel=\"noopener\">Gilead announced a $3.15 billion deal to buy Tubulis, a clinical-stage ADC developer<\/a> with platform technologies that yield ADCs with better stability and larger capacity to carry more drug payload. The week also included <a href=\"https:\/\/medcitynews.com\/2026\/04\/antibody-drug-conjugate-cancer-oncology-sidewinder-stipple-adc-startup\/\" target=\"_blank\" rel=\"noopener\">mega-financing rounds from startups Sidewinder Therapeutics and Stipple Bio<\/a>, each developing new approaches to improving the targeting ability of ADCs.<\/p>\n<p><em>Photo by Flickr user <a href=\"https:\/\/flic.kr\/p\/9kke5a\" target=\"_blank\" rel=\"noopener\">Paul Sableman<\/a> via a Creative Commons <\/em><a href=\"https:\/\/creativecommons.org\/licenses\/by\/2.0\/\" target=\"_blank\" rel=\"noopener\"><em>license<\/em><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better efficacy, CrossBio\u2019s dual approach could also fight drug resistance. <\/p>\n","protected":false},"author":25932,"featured_media":13575,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"featured_image_focal_point":[],"homepage_placement":"top","homepage_placements":{"top":true,"featured":true,"sidebar":false},"homepage_alternative_layout":false,"featured_categories":[54,69],"hide_from_feed":false,"footnotes":""},"categories":[69,54,60],"tags":[28188,42355,14217,12102,53557,46027,2196,39249,8316],"class_list":["post-146428","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","category-pharma-channel","category-startup-channel","tag-antibody-drug-conjugate","tag-biopharma-nl","tag-cancer","tag-clinical-trials","tag-crossbridge-bio","tag-deals","tag-eli-lilly","tag-mergers-and-acquisitions","tag-startups"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors - MedCity News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors - MedCity News\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better efficacy, CrossBio\u2019s dual approach could also fight drug resistance.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/\" \/>\n<meta property=\"og:site_name\" content=\"MedCity News\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-15T14:46:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-15T14:46:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/02\/5469618669_c48bfab7ba_c.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"583\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frank Vinluan\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@frankvinluan\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frank Vinluan\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/\"},\"author\":{\"name\":\"Frank Vinluan\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"headline\":\"Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors\",\"datePublished\":\"2026-04-15T14:46:40+00:00\",\"dateModified\":\"2026-04-15T14:46:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/\"},\"wordCount\":523,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/02\/5469618669_c48bfab7ba_c.jpg\",\"keywords\":[\"antibody drug conjugate\",\"biopharma nl\",\"cancer\",\"Clinical Trials\",\"CrossBridge Bio\",\"Deals\",\"Eli Lilly\",\"Mergers and Acquisitions\",\"Startups\"],\"articleSection\":[\"BioPharma\",\"Pharma\",\"Startups\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/\",\"url\":\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/\",\"name\":\"Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors - MedCity News\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/02\/5469618669_c48bfab7ba_c.jpg\",\"datePublished\":\"2026-04-15T14:46:40+00:00\",\"dateModified\":\"2026-04-15T14:46:41+00:00\",\"author\":{\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"breadcrumb\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/#primaryimage\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/02\/5469618669_c48bfab7ba_c.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/02\/5469618669_c48bfab7ba_c.jpg\",\"width\":800,\"height\":583},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/medcitynews.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/medcitynews.com\/#website\",\"url\":\"https:\/\/medcitynews.com\/\",\"name\":\"MedCity News\",\"description\":\"Healthcare technology news, life science current events\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/medcitynews.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\",\"name\":\"Frank Vinluan\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"caption\":\"Frank Vinluan\"},\"description\":\"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/frankvinluan\/\",\"https:\/\/x.com\/frankvinluan\"],\"url\":\"https:\/\/medcitynews.com\/author\/fvinluan\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors - MedCity News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors - MedCity News","og_description":"Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better efficacy, CrossBio\u2019s dual approach could also fight drug resistance.","og_url":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/","og_site_name":"MedCity News","article_published_time":"2026-04-15T14:46:40+00:00","article_modified_time":"2026-04-15T14:46:41+00:00","og_image":[{"width":800,"height":583,"url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/02\/5469618669_c48bfab7ba_c.jpg","type":"image\/jpeg"}],"author":"Frank Vinluan","twitter_card":"summary_large_image","twitter_creator":"@frankvinluan","twitter_misc":{"Written by":"Frank Vinluan","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/#article","isPartOf":{"@id":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/"},"author":{"name":"Frank Vinluan","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"headline":"Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors","datePublished":"2026-04-15T14:46:40+00:00","dateModified":"2026-04-15T14:46:41+00:00","mainEntityOfPage":{"@id":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/"},"wordCount":523,"commentCount":0,"image":{"@id":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/02\/5469618669_c48bfab7ba_c.jpg","keywords":["antibody drug conjugate","biopharma nl","cancer","Clinical Trials","CrossBridge Bio","Deals","Eli Lilly","Mergers and Acquisitions","Startups"],"articleSection":["BioPharma","Pharma","Startups"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/","url":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/","name":"Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors - MedCity News","isPartOf":{"@id":"https:\/\/medcitynews.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/#primaryimage"},"image":{"@id":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/02\/5469618669_c48bfab7ba_c.jpg","datePublished":"2026-04-15T14:46:40+00:00","dateModified":"2026-04-15T14:46:41+00:00","author":{"@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"breadcrumb":{"@id":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/#primaryimage","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/02\/5469618669_c48bfab7ba_c.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/02\/5469618669_c48bfab7ba_c.jpg","width":800,"height":583},{"@type":"BreadcrumbList","@id":"https:\/\/medcitynews.com\/2026\/04\/eli-lilly-crossbridge-bio-acquisition-antibody-drug-conjugate-dual-payload-adc-lly\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/medcitynews.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors"}]},{"@type":"WebSite","@id":"https:\/\/medcitynews.com\/#website","url":"https:\/\/medcitynews.com\/","name":"MedCity News","description":"Healthcare technology news, life science current events","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medcitynews.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35","name":"Frank Vinluan","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/image\/","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","caption":"Frank Vinluan"},"description":"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan","sameAs":["https:\/\/www.linkedin.com\/in\/frankvinluan\/","https:\/\/x.com\/frankvinluan"],"url":"https:\/\/medcitynews.com\/author\/fvinluan\/"}]}},"_links":{"self":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/users\/25932"}],"replies":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/comments?post=146428"}],"version-history":[{"count":3,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146428\/revisions"}],"predecessor-version":[{"id":146431,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146428\/revisions\/146431"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media\/13575"}],"wp:attachment":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media?parent=146428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/categories?post=146428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/tags?post=146428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}